• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
KROS

KROS

Keros Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD10.50

-0.05 (-0.47%)

Rating:B-

Company Profile

CEO

Jasbir S. Seehra

IPO Date

2020-04-08

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$10.52

Prev. Close

$10.55

Day Low

$10.38

Day High

$10.57

52W Low

$9.79

52W High

$22.55

Market Cap

$0.34B

Volume

0.19M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

18.2%

Avg Negative

1.6%

Avg Neutral

80.4%

News Feed

Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

GlobeNewsWire·6/22/2021·↑ positive

Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2nd Translational Research E-Conference

GlobeNewsWire·3/5/2021·↑ positive

Keros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewsWire·11/17/2020·↑ positive

Keros Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewsWire·11/12/2020·↑ positive

Keros Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewsWire·11/10/2020·↑ positive

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results

GlobeNewsWire·11/10/2020·↑ positive

Keros Therapeutics to Present at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition

GlobeNewsWire·11/4/2020·↑ positive

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results

Yahoo·8/13/2020·↑ positive

Keros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease Series

Yahoo·8/10/2020·↑ positive

Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update

Yahoo·8/4/2020·↑ positive